What is Parkinson’s Disease
Parkinson’s disease is the most common cause of Parkinsonism and is the second most common neurodegenerative disease, after Alzheimer’s disease. Although descriptions of the condition appeared before the nineteenth century, it was James Parkinson’s eloquent account in 1817 that fully documented the clinical features of the illness now bearing his name.
The identification of dopamine deficiency in the brains of people with Parkinson’s disease and the subsequent introduction of replacement therapy with levodopa represent a considerable success story in the treatment of neurodegenerative illness in general. There remain, however, a number of significant management problems in Parkinson’s disease, particularly in the advanced stages of the condition.
Incidence Of Parkinson’s disease
Parkinson’s disease affects 1% of the population over 65 years of age, rising to 2% over the age of 80. One in 20 patients is, however, diagnosed before their 40th year. It is estimated that 110,000 people have Parkinson’s disease in the UK. The condition is found worldwide, with variability in prevalence estimates most likely reflecting study methodology, rather than real differences.
Most epidemiological studies have indicated a small male-to-female predominance. Drug-induced Parkinsonism is also called as symptomatic Parkinsonism. It affects minor group of individuals who are exposed to dopamine receptor blocking agents including neuroleptics and some labyrinthine sedatives.
Symptoms Of Parkinson’s disease
- Bradykinesia is common for Parkinsonism in general.
- If a person does not have slowness of movement, they cannot have either Parkinsonism or Parkinson’s disease.
- Rest tremor, extrapyramidal rigidity (so-called lead pipe and/or cog-wheel) and postural instability comprise the remaining classic tetrad of clinical features for
- Asymmetry of signs at disease onset is very common.
- Autonomic dysfunction may occur in Parkinson’s disease.
- The patient may drool and have greasy skin (seborrhoea). Urogenital difficulties, with erectile dysfunction in males and urinary urgency in both sexes, are commonly encountered.
- Frank incontinence is, however, rare.
- Constipation is invariable and is multifactorial in origin.
- Falling blood pressure on standing (postural hypotension) may contribute to falls later in the disease course.
- Depression affects approximately 40% of people with Parkinson’s disease and is a major determinant of both carer stress and nursing home placement.
Causes Of Parkinson’s disease
Both genetic and environmental factors have been implicated as a cause of Parkinson’s disease. While opinions were initially polarized, it now seems probable that in the majority of cases there is an admixture of influences, with environmental factors precipitating the onset of Parkinson’s disease in a genetically susceptible individual. Environmental factors became preeminent in the 1980s when drug addicts attempting to manufacture pethidine accidentally produced a toxin called MPTP (1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine). Ingestion or inhalation of MPTP rapidly produced a severe Parkinsonian state, indistinguishable from advanced Parkinson’s disease.
Diagnosis Of Parkinson’s disease
- The diagnosis of Parkinson’s disease is a clinical criterion. In young-onset or clinically atypical Parkinson’s disease, a number of investigations may be appropriate.
- These include copper studies and DNA testing to exclude Wilson’s disease and Huntington’s disease, respectively.
- Brain imaging by computed tomography (CT) or magnetic resonance imaging (MRI) may be necessary to exclude hydrocephalus, cerebrovascular disease or basal ganglia abnormalities suggestive of an underlying metabolic cause.
- When there is difficulty in distinguishing Parkinson’s disease from essential tremor, a form of functional imaging called FP-CIT SPECT (also known as DaTSCAN) may be useful, as this technique can sensitively identify loss of nigrostriatal dopaminergic terminals in the striatum. Thus, in essential tremor, the SPECT scan is normal, whereas, in Parkinson’s disease, reduced tracer uptake is seen
Treatment Of Parkinson’s disease
A number of factors which includes age, severity and type of disease (tremor-dominant versus bradykinesia-dominant) and co-morbidity, are taken into account for the treatment of Parkinson’s dsease. The efficacy and tolerability of levodopa in Parkinson’s disease were first described when the drug was started in low doses and gradually increased thereafter.
Examples of non-neuroleptic drugs associated with drug-induced Parkinsonism Sodium valproate Tetrabenazine Calcium channel blockers (e.g. cinnarizine) Amiodarone Lithiuma Phenelzineb Amphotericin Bc 5-Fluorouracilb Vincristine–adriamycinb Pethidineb a Lithium causes postural tremor.
This syndrome comprises premature wearing off of the antiparkinsonian effects of levodopa, and response fluctuations. The wearing-off effect is the time before a patient is due their next dose of medication, during which they become increasingly bradykinetic. Response fluctuations can include dramatic swings between gross involuntary movements (dyskinesias) and a frozen, immobile state.
The rapid and sudden switching between the dyskinetic state and profound akinesia is also termed the ‘on–off’ phenomenon. If this occurs rapidly and repeatedly, the term ‘yo-yo-ing’ is sometimes used. These problems emerge at a rate of approximately 10% per year so that by 10 years into their illness all Parkinson’s disease patients can expect to experience such unpredictable responses.
Notably, however, levodopa-induced dyskinesias and fluctuations develop earlier in younger Parkinson’s disease patients than in older patients. On–off episodes may be extremely disabling and remain a major therapeutic challenge in the management of Parkinson’s disease.